Phathom Pharma: Positive Topline Results from Pivotal Phase 3 Esophagitis Trial

 

• Vonoprazan met its primary non-inferiority endpoints in both healing and maintenance phases
  
  

• Vonoprazan demonstrated superior healing rates in patients with moderate-to-severe disease at Week 2 versus lansoprazole (PREVACID®), a proton pump inhibitor (PPI)
  
  

• Vonoprazan demonstrated superior maintenance of healing in all patients and patients with moderate-to-severe disease versus lansoprazole at Week 24
  
  

• New Drug Application (NDA) submission planned for H1 2022 targeting the following indications: healing of all grades of erosive esophagitis (EE) and relief of heartburn, and maintenance of healing of all grades of EE and relief of heartburn
  
  

• Phathom to host conference call today, October 18, 2021, at 8:30 am ET

Conference call on the PHALCON-EE trial results
Phathom will host a webcasted conference call today, October 18, 2021, at 8:30 am ET to discuss the PHALCON-EE study results.

To view the live webcast, visit https://investors.phathompharma.com/news-events/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time.

A replay of the webcast and the slide presentation will be available after the meeting on the News & Events section of the Phathom website.

https://finance.yahoo.com/news/phathom-pharmaceuticals-announces-positive-topline-110000500.html